# Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

> **NCT02504216** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 6564 (actual)

## Conditions studied

- Peripheral Artery Disease

## Interventions

- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)
- **DRUG:** Rivaroxaban-Placebo

## Key facts

- **NCT ID:** NCT02504216
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-18
- **Primary completion:** 2019-11-27
- **Final completion:** 2020-01-09
- **Target enrollment:** 6564 (ACTUAL)
- **Last updated:** 2020-12-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02504216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02504216, "Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT02504216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*